A Study of Psilocybin for PTSD

Description

The proposed open-label, controlled study at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) will test the following primary hypotheses in adult patients with chronic PTSD who are currently taking a serotonin reuptake inhibitor: psilocybin therapy will be feasible and safe for participants, significantly remediate PTSD symptoms, and enhance wellbeing and quality of life. In addition, the study will examine whether elements of evidence-based trauma-focused psychotherapy enhance treatment response when paired with psilocybin.

Conditions

Post Traumatic Stress Disorder

Study Overview

Study Details

Study overview

The proposed open-label, controlled study at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) will test the following primary hypotheses in adult patients with chronic PTSD who are currently taking a serotonin reuptake inhibitor: psilocybin therapy will be feasible and safe for participants, significantly remediate PTSD symptoms, and enhance wellbeing and quality of life. In addition, the study will examine whether elements of evidence-based trauma-focused psychotherapy enhance treatment response when paired with psilocybin.

Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy

A Study of Psilocybin for PTSD

Condition
Post Traumatic Stress Disorder
Intervention / Treatment

-

Contacts and Locations

Baltimore

Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States, 21224

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 21 to 75 years old
  • * Have given written informed consent
  • * Have a confirmed DSM-5 diagnosis of Post-Traumatic Stress Disorder with symptom duration \>= 6 months
  • * Have a baseline CAPS-5 score of \>=35
  • * Currently taking a serotonin reuptake inhibitor (e.g. selective serotonin reuptake inhibitor (SSRI), serotonin and norepinephrine reuptake inhibitor (SNRI), at a stable dose for at least two weeks.
  • * Be judged by study team clinicians to be at low acute risk for suicidality
  • * Be medically stable as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests
  • * Agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that he/she consumes on a usual morning, before arriving at the research unit on the mornings of drug session days. If the participant does not routinely consume caffeinated beverages, he/she must agree not to do so on session days.
  • * Agree to refrain from using any psychoactive drugs, including alcoholic beverages within 24 hours of each drug administration. The exception is caffeine and nicotine.
  • * Agree not to take any as needed (PRN) medications on the mornings of drug sessions
  • * Agree not to take sildenafil (Viagra®), tadalafil, or similar medications within 72 hours of each drug administration.
  • * Agree that for one week before each drug session, he/she will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the study investigators. Exceptions will be evaluated by the study investigators and will include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals.
  • * Have limited lifetime use of hallucinogens (the following criteria are preferred: no use in the past 2 years; total hallucinogen use less than 10 times)
  • * Have at least a high school level of education or equivalent (e.g. GED).
  • * Weigh between 40kg - 120kg.
  • * (for female participants) Agree to use highly effective birth control measure within two weeks of completing the dosing sessions.

Ages Eligible for Study

21 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Johns Hopkins University,

Sandeep Nayak, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

2027-05